Beyond Lithium in the Treatment of Bipolar Illness

Robert M. Post, M.D., Mark A. Frye, M.D., Kirk D. Denicoff, M.D., Gabriele S. Leverich, L.C.S.W., Tim A. Kimbrell, M.D., and Robert T. Dunn, M.D.

Dramatic changes have recently occurred in the availability of treatment options for bipolar illness. Second generation mood stabilizing anticonvulsants carbamazepine and valproate are now widely used as alternatives or adjuncts to lithium. High potency benzodiazepines are also used as alternatives to typical neuroleptics, and now atypical neuroleptics are demonstrating efficacy and better side-effects profiles than the typicals. Thyroid augmentation strategies and dihydropyridine L-type calcium channel blockers require further clinical trials to define their role. Putative third generation mood stabilizing anticonvulsants

lamotrigine, gabapentin, and topiramate have unique mechanisms of action and deserve further systematic study, as does the potential role for nonconvulsive brain stimulation with repeated transcranial magnetic stimulation (rTMS). These and a host of other potential treatment options now require a new generation of clinical trials to help identify clinical and biological markers of response and optimal use alone and in complex combination therapeutic regimens. [Neuropsychopharmacology 19:206-219, 1998] Published by Elsevier Science Inc.

KEY WORDS: Carbamazepine; Valproate; Calcium channel blockers; Lamotrigine; Gabapentin; rTMS

There is increasing recognition of the inadequacy of "lithium treatment" in bipolar illness, even with adjunctive antidepressants and neuroleptics (Maj et al. 1989; Aagaard and Vestergaard 1990; O'Connell et al. 1991; Vestergaard 1992; Gitlin et al. 1995). Some bipolar patient subtypes are particularly prone to lithium non-responsiveness; among these are patients with dysphoric mania and rapid cycling; a negative family history for bipolar illness in first-degree relatives; the episode sequence pattern of depression-mania-well interval (i.e., the D-M-I pattern as opposed to the M-D-I pattern); more than three episodes prior to the initiation of prophylaxis (Sarantidis and Waters 1981; Gelenberg et

al. 1989; O'Connell et al. 1991; Denicoff et al. 1997); a history of co-morbid substance abuse; and those patients with a history of head trauma or other such medical co-morbidities as multiple sclerosis, etc.

In addition, it is recognized that patients with initial excellent responses to lithium can begin to develop breakthrough episodes in subsequent extended years of follow-up (Maj et al. 1989; Post et al. 1992). In our series of 66 lithium-refractory patients, 23 (34.9%) seem to have developed their lithium-refractoriness over more prolonged periods of follow-up, in a pattern resembling tolerance.

Another recently described route to refractoriness has been found in patients who were excellent responders to lithium, but then discontinued treatment (on the basis of either noncompliance or physician acquiescence), experienced a relapse, and then failed to re-respond once lithium was reinstituted (Post et al. 1992, 1993; Koukopoulos et al. 1995). This type of lithium discontinuation-induced refractoriness can be quite malignant, with patients failing to re-respond, even when lithium is augmented with a variety of the other alter-

From the Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland, USA.

Address correspondence to: Robert M. Post, M.D., Chief Biological Psychiatry Branch, NIMH, Bldg. 10, Room 3N212, 10 Center Drive MSC 1272, Bethesda, Maryland 20892-1272, USA.

Received February 23, 1998; accepted February 23, 1998.

Table 1. Controlled Studies of Carbamazepine (CBZ) and Oxcarbazepine (OXCZB) in Acute Mania

Study	n ^a	Diagnosis	Design	Doses (mg/day) [blood level]	Other Drugs	Duration	Outcome Measures	Results
Ballenger and Post 1978; Post et al. 1984a, 1987	19 CBZ 19 Placebo	Manic	D-BI (B-A-B-A) randomized	600–2,000-mg CBZ [8–12 µg/ml]	None	11–56 Days	Bunney-Hamburg BPRS	12/19 (63%) Improved time course similar to neuroleptics; frequent relapses on placebo substitution
Okuma et al. 1979	30 CBZ 25 CPZ	Manic	D-BI. vs. CPZ randomized	300–900-mg CBZ [2.7–11.7 µg/ml] [mean = 7.2 ± 3.4] 150–450-mg CPZ [2.6–311.4 µg/ml]	Bedtime hypnotics	3–5 Weeks	CPRG	21/30 (70%) Improved on CBZ 15/25 (60%) Improved on CPZ (moderate to marked) Fewer side effects on CBZ Slightly faster onset with CBZ
Grossi et al. 1984	15 CBZ 17 CPZ	Manic	D-BI. vs. CPZ randomized	200–1,200-mg CBZ [mean 655.5 ± 295.5] 200–800 mg CPZ [mean 362.5 ± 166.83]	Bedtime hypnotics	3 Weeks	MSRS BMS	10/15 (67%) improved on CBZ 10/17 (59%) improved on CPZ (moderate to marked) Fewer side effects with CBZ than CPZ Slightly faster onset with CBZ
Klein et al. 1984	23 CBZ 20 Placebo	Manic/ excited S/SA	D-BI. vs. placebo randomized	600–1,200-mg CBZ addition to halo	Halo [8–12 µg/ml]	5 Weeks 15–45 mg all patients	BPRS GCI	13/23 (57%) BPRS improvement CBZ+halo 11/20 (55%) BPRS improvement plac+halo Improvement in GCI in both groups
Muller and Stoll 1984	10 OXCZB 10 Halo	Mania	D-BI. vs. halo randomized	900–1,200 mg OXCZB 15–20 mg halo	Halo and hypnotics	2 Weeks	BRMS	BRMS scores decreased in both groups; onset faster with OXCZB
Goncalves and Stoll 1985	6 CBZ 6 Placebo	Manic SA	D-BI. vs. placebo randomized	200–1,200 mg CBZ	Halo and hypnotics	3 Weeks	MS-M	6/6 CBZ better than placebo ($p < .01$)
Emrich et al. 1985	7 OXCZB 5 placebo	Manic psychosis	D-BI. (B-A-B)	1,800–2,100 mg (max. dosage range) OXCZB	None	Variable	IMPS	6/7 (86%) Improved with OXCZB (>25% Improvement on IMPS)
Lenzi et al. 1986	11 CBZ 11 Li	Excitation psychosis	D-BI. vs. Li randomized	400–1,600 mg CBZ [7–12 µg/ml] 300–900 mg Li [0.6–1.2 mEq/l]	CPZ all patients	19 Days average	BPRS CGI	Significant improvement with CBZ and Li on CGI and BPRS CBZ group required less CPZ CBZ less paranoia and EPS
Stoll et al. 1986	14 CBZ 18 Halo	Manic	Randomized vs. halo	600–1,200 mg CBZ 5–30 mg halo	Neuroleptics Hypnotics	3 Weeks	MS-M	12/14 (86%) Improved on CBZ 12/18 (67%) Improved on halo (good to very good)
Desai et al. 1987	5 CBZ 5 Placebo	Manic	D-BI. vs. placebo addition to Li randomized	400 mg fixed dose CBZ	Li all patients [0.5–1.7 mEq/l]	4 Weeks	BRMS GMS	CBZ + Li better BRMS and GMS than Li alone ($p < .05$)
Lerer et al. 1987	14 CBZ 14 Li	Manic	D-BI. vs. Li randomized	600–2,600-mg CBZ [3.2–14 µg/ml] 900–3,900-mg Li [0.2–2.0 mEq/l]	Chloral hydrate barbiturates H.S.	4 Weeks	CGI BPRS MSRS	4/14 (29%) Improved CGI score on CBZ ($p < .05$) 11/14 (79%) Improved CGI score on Li BPRS and MSRS scores improved with both CBZ and Li, nonsignificantly No significant differences
Lusznat et al. 1988	22 CBZ 22 Li	Manic/ hypo- manic	D-BI. vs. Li randomized	200-mg CBZ until serum lvl 6–12 µg/ml 400-mg Li until serum lvl 0.6–1.4 mmol/l	CPZ, halo, neuroleptics	6 Weeks	BRMS	
Okuma et al. 1988	103 CBZ 98 Placebo	Manic	D-BI. vs. placebo		Antipsychotics		Global improvement rate	50% Global improvement rate on CBZ 30% Global improvement rate on placebo (moderate to marked)

(continued)

Table 1. (continued)

Study	n ^a	Diagnosis	Design	Doses (mg/day) [blood level]	Other Drugs	Duration	Outcome Measures	Results
Brown et al. 1989	8 CBZ 9 Halo	Manic	D-Bl. vs. halo randomized	400–1,600 mg CBZ 20–80 mg halo	CPZ	4 Weeks	YMS PMS	6/8 (75%) Marked improvement on CBZ 3/9 (33%) Marked improvement on halo CBZ slower onset, higher completion rate (75%) vs. 22%), fewer EPS Both groups highly significant antimanic effect on all scales No significant difference between groups CBZ group needed less levomepromazine Both groups significantly lowered BRMS score Side effects 3 1/2 times greater in halo group
Moller et al. 1989	11 CBZ 9 Placebo	Manic or SA	D-Bl. vs. placebo	600 mg CBZ	Halo 24 mg all patients Levo- mepromazine	3 Weeks	BRMS BPRS MS-M	BRMS BPRS MS-M
Emrich 1990	19 OXCZB 19 Halo	Manic	D-Bl. vs. halo	2,400-mg mean dose OXCBZ		15 Days	BRMS	BRMS
Emrich 1990	28 OXCZB 24 Li	Manic	D-Bl. vs. Li	42-mg mean dose halo 1,400-mg mean dose OXCBZ		15 Days	BPRS	Both groups significantly lowered BRMS score Side effects slightly higher in OXCZB group
Okuma et al. 1990	50 CBZ 51 Li	Manic	D-Bl. vs. Li	400–1,200-mg CBZ [mean = 7.3 µg/ml] 400–1,200-mg Li [mean = 0.46 mEq/l]	Neuroleptics Bedtime hypnotics	4 Weeks	CPRG	31/50 (62%) Improved on CBZ 30/51 (59%) Improved on Li No significant difference between groups CBZ onset earlier, greater EPS
Small et al. 1991	24 CBZ 24 Li	Manic	D-Bl. vs. Li randomized	700–1036-mg CBZ [30–37 mmol/l] 1,035–1,278 mg Li [0.6–0.9 mmol/l]	Hypnotics	6–8 Weeks	SDMS-D&M YMS BPRS CGI	8/24 (33%) Improved on CBZ 8/24 (33%) Improved on Li No significant difference between groups after 8 weeks
Total of all 19 studies	355 pts. on CBZ 64 pts. on OXCZB 146 pts. on Li 98 pts. on neuroleptics 162 pts. on placebo							123/203 (61%) Improved on CBZ 6/7 (86%) Improved on OXCZB 49/89 (55%) Improved on Li 51/89 (57%) Improved on neuroleptics

^a Total number of subjects who completed study and were used for analysis.

Abbreviations in columns: n: CBZ = Carbamazepine; OXCZB = Oxcarbazepine; Li = Lithium; CPZ = Chlorpromazine; Halo = Haloperidol; **Diagnosis:** S = Schizophrenic; SA = Schizoaffective; **Design:** D-Bl. = Double Blind; B-A-B = off-on-off; **Outcome Measures:** Bunney-Hamburg = Bunney-Hamburg Rating Scale; BPRS = Brief Psychiatric Rating Scale; CPRG = Clinical Psychopharmacology Research Group rating scale for mania; MSRS = Manic State Rating Scale; BMS = Bipolar Manic Scale; GCI = Global Clinical Impressions Scale; BRMS = Bech-Raefelson Mania Scale; MS-M = Murphy Scale for Mania; IMPS Inpatient Multidimension Rating Scale; CGI = Clinical Global Impression Scale; GMS = Global Mania Scale; MSRS = Beigel-Murphy State Rating Scale; YMS = Young Mania Scale; PMS = Petterson Mania Scale; SDMS-D&M = Manic subsection of the Depression & Mania Scale; **Results:** EPS = Extrapyramidal side effects

native treatments described below; or more mild, and just require greater neuroleptic augmentation.

Thus, lithium shows parallels to the role of penicillin in the treatment of infectious diseases. Penicillin was initially heralded as a miracle drug (which it was), until patterns of nonresponse or treatment-resistance emerged, and a variety of alternative treatments were required. In cases of tuberculosis or AIDS-related opportunistic infections, for example, patients can require complex combination therapy to bring these more malignant infections under control. A similar sequence of adjuncts and alternatives to lithium treatment is now required for many patients with lithium nonresponsive affective illness.

Some of these emerging alternatives are described below, two of which (the mood-stabilizing anticonvulsants carbamazepine and valproate) have already gained wide acceptance in clinical practice. Valproate recently has been FDA-approved for first-line treatment of acute mania. Many of the other promising approaches are more investigational, but, in many instances, clinical practice is again ahead of more formal controlled clinical trials.

CARBAMAZEPINE

Nineteen double-blind studies of various methodologies compared with placebo ($N = 5$), compared with neuroleptics ($n = 6$), compared with lithium ($n = 6$), and B-A-B-A (off-on-off-on) designs ($n = 2$) document the acute antimanic efficacy of carbamazepine or its congener oxcarbazepine (Table 1). Perhaps most revealing is the clear documentation of responsivity in individual patients using double-blind, placebo substitution designs that demonstrate efficacy, reconfirmed with placebo-related exacerbation and re-responsiveness after drug institution on a blind basis (Ballenger and Post 1978; Post et al. 1984a; Post et al. 1996a). Anti-depressant effects are much less well documented and require further controlled study (Post et al. 1994). However, in long-term prophylaxis, the ability of carbamazepine to prevent recurrent depressive episodes seems as prominent as the ability to prevent recurrent manias in both controlled and partially controlled double-blind studies as well as in open studies (Table 2), with an overall moderate to marked response rate of approximately 62%. Although many of these double-blind studies have been criticized on methodological grounds, other designs used, such as mirror image designs in treatment-refractory patients and B-A-B-A designs, have been cited by Prien and Gelenberg (1989) as more convincing.

As with lithium, a subgroup of patients who are initially responsive to carbamazepine alone or with adjunctive treatment with other agents seems to lose efficacy with the development of tolerance (Post et al. 1990; Leverich et al. unpublished data 1998). Loss of respon-

siveness may have accounted for the large drop-out rate in the follow-up study of Frankenburg et al. (1988), although the percentage attributable to tolerance is unknown.

In our prospective follow-up of initial responders, 13 of the 29 carbamazepine responders (45%) followed in long-term prophylaxis for an average of 6.9 years developed a loss of efficacy after an average of 2.8 years of carbamazepine treatment (Leverich et al. unpublished data). This high percentage may be unrepresentative of the general population because of the relatively treatment-refractory and rapid-cycling nature of the patients who were started on carbamazepine in the acute inpatient phase of this study. However, it would seem that at least a subgroup of patients may develop tolerance to carbamazepine in the treatment of bipolar illness, similar to the even higher percentage of tolerance development using carbamazepine in the treatment of trigeminal neuralgia (Fromm and Terrence 1987).

Weiss et al. (1995a) have described some of the potential molecular mechanisms involved in the loss of anticonvulsant efficacy to carbamazepine in the treatment of amygdala-kindled seizures in rodents. These data suggest that tolerance to carbamazepine is pharmacodynamic rather than pharmacokinetic and may represent the loss of illness-induced adaptations during carbamazepine treatment. As such, these preclinical data would suggest the potential utility of switching to drugs with different mechanisms of action or returning to carbamazepine after a time-off period. Several cases studies support the possibility of the usefulness of such a maneuver (Pazzaglia and Post 1992; and unpublished data), although larger long-term prospective studies are required in order to develop the optimal intervention paradigms for the treatment of carbamazepine tolerance.

In patients who remain successfully treated with carbamazepine, there does not seem to be a very high rate of discontinuation-related refractoriness as observed with lithium; all 10 patients re-responded during a second double-blind trial. However, one schizoaffective patient who showed a rapid antimanic re-response remained psychotic for a longer period (Post et al. unpublished observations). On this issue, as well, longer-term studies in a larger number of patients are required in order to assess this potential liability more definitively across different psychotropic medications.

The clinical predictors of response to carbamazepine have not been adequately delineated. However, there is preliminary evidence that, as in lithium treatment, rapid-cycling patients do not respond as well to carbamazepine monotherapy as do nonrapid-cycling patients (Okuma 1993; Denicoff et al. 1997); whereas, those with a negative family history for bipolar illness in first-degree relatives may be included among those responsive to carbamazepine (Post et al. 1987), as are those with more severe and discrete episodes of depres-

Table 2. Controlled and Partially Controlled Studies of Carbamazepine (CBZ) and Oxcarbazepine Prophylaxis in Affective Illness

Investigators (Design)	Placebo	CBZ Responders	% Response	Lithium Responders	% Response
Ballenger & Post 1978 (D-BI, M)		6/7	86%	—	—
Post et al. 1983					
Okuma et al. 1981 (D-BI)	2/9	6/10	60%	—	—
Svestka et al. 1985 (R)		14/24	62%	12/24	50%
Kishimoto & Okuma 1986 (C)		(?/18)	↓ # hosp vs. Li	—	—
Cabrera et al. 1986 ^a (R)		2/4	50%	3/6	50%
Placidi et al. 1986 (D-BI, R)		21/29	72%	20/27	74%
Watkins et al. 1987 (D-BI, R)		16/19	84%	15/18	83%
Elphick et al. 1988 (D-BI, R)		3/8	37%	8/11	73%
Lusznat et al. 1988 (D-BI, R)		?/9	↓ fewer depressions	?/5	—
Bellaire et al. 1990 (R)		34/40	85%	42/49	86%
DiCostanzo & Schifano 1991 (R) ^b		(?/16)	Li + CBZ fewer episodes than Li alone	(?/16)	—
Mosolov 1991 (R?)		?/30	Episodes ↓ 58%	?/30	Episodes ↓ 54%
Coxhead et al. 1992 (D-BI, R)		7/15	47%	7/16	44%
Denicoff et al. 1997 (B, R)		11/35	31%	14/42	33%
Greil et al. 1997a (BP)(R)		23/43	53%	43/60	72%
Greil et al. 1997b (SA)(R)		15/32	47%	16/37	43%
Wolf et al. 1997 (D-BI)		59/84	70%	59/84	70%
All controlled and partially controlled studies		217/350	62%	239/374	64%
All open studies		390/629 ^c	62%		

Abbreviations: double-blind (D-BI), Crossover (C), Mirror image (M), or Randomized (R), (—) not stated; Bipolar (BP), Schizoaffective (SA).

^a Oxcarbazepine.

^b Pseudo randomized to Li vs. CBZ & Li; greater antimanic and antidepressant efficacy in first year vs. Li alone.

^c Includes carbamazepine combination therapies.

sion and those who have greater decrements in T_4 and free T_4 during treatment with the drug (Roy-Byrne et al. 1984; Post et al. 1986). In the study of Denicoff et al. (1997), the combination of lithium and carbamazepine proved much more effective for rapid-cycling patients than monotherapy with either agent. Ketter et al. (1996) found that patients with global hypermetabolism, and particularly in the region of the left insula, seem more responsive to carbamazepine as compared with depressed patients with a more classical picture of frontal lobe or left insula hypometabolism. It is these latter patients with the typical depressive pattern of frontal hypometabolism who seem more responsive to the dihydropyridine L-type calcium channel blocker nimodipine.

VALPROATE

Valproate is now FDA-approved for the treatment of acute mania based on several placebo-controlled clinical trials demonstrating efficacy (Pope et al. 1991; Bowden et al. 1994). However, in the study of Bowden et al., only 50% of the patients showed a 50% or greater response at the end of the 3-week study, findings in parallel with those of lithium. These data indicate that although valproate is highly effective as compared with placebo, many patients remain inadequately responsive and re-

quire adjunctive medications in order to optimize either the time frame or completeness of clinical response.

In this regard, Keck et al. (1993) have used loading doses of valproate (20 mg/kg/day) from the beginning of treatment and find it generally well tolerated and able to achieve higher blood levels more readily. This is convergent with the data of Bowden et al. (1996), indicating that patients with blood levels over 45 $\mu\text{g/ml}$ were better early responders to valproate. Open studies by a variety of investigators indicate that valproate has prophylactic effects against recurrences of both acute mania and acute depression in a variety of patients subgroups, including those with dysphoric mania, rapid cycling, and a variety of other traditionally inadequately treated subgroups of bipolar patients (Lambert 1984; Emrich et al. 1984; Fawcett 1988; Calabrese and Delucchi 1989, 1990; Post 1989; Schaff et al. 1993; Lambert and Venaud 1995).

In particular, we and others have noted many patients with excellent responses to valproate who previously were unresponsive to both lithium and carbamazepine. Conversely, we have observed some patients who responded to carbamazepine but failed valproate (Post et al. 1984b), further suggesting that response or nonresponse to one anticonvulsant is not necessarily predictive of responsivity to another (Calabrese et al. 1992; Schaff et al. 1993).

In our initial series of 27 patients followed for an average of 5.8 years, we observed that four of 15 (27%) initial responders developed a pattern consistent with a loss of efficacy via tolerance after an average of 2.9 years of valproate treatment (Post et al. unpublished data), and McElroy et al. (personal communication) have also reported a small percentage of patients with loss of efficacy to valproate. Clinical predictors and therapeutic maneuvers remain to be more definitively delineated.

CALCIUM CHANNEL BLOCKERS

A substantial, but partially mixed, literature review supports the use of verapamil in acute mania (Table 3), although several recent studies do not support this perspective (Janicak et al. 1994; Walton et al. 1996). Even the positive double-blind series of Hoschl and Kozeny (1989) in acute mania was unable to demonstrate significant acute antidepressant effects. In light of this ambiguous profile and less than satisfactory response in acute depression, we elected to study a different calcium channel blocker with a different profile of physiochemical and biochemical properties—the dihydropyridine L-type calcium channel blocker nimodipine.

Nimodipine has greater lipid solubility and better penetration into the central nervous system (Freedman and Waters 1987) and is reported to be problematic with tolerance in the treatment of migraine as compared with other calcium channel blockers. Moreover, nimodipine has a different profile of anticonvulsant effects in animal models and, in contrast to verapamil, blocks cocaine-induced hyperactivity and its associated dopamine overflow (Pani et al. 1990).

Five of the first 12 patients treated with nimodipine showed clinically relevant improvement using a double-blind B-A-B, and in some instances, B-A-B-A placebo-substitution design (Pazzaglia et al. 1993). Using this design, response could be confirmed in patients with very different cycle frequencies, and appropriate statistical techniques could be applied in single-case analyses, as described by McDermut et al. (1995).

In an extension of the original study of Pazzaglia et al. (1993), we have now studied a total of 36 patients on nimodipine, 30 of whom were evaluable. Ten of these patients showed clinically relevant degrees of response as rated by marked to moderate response on the clinical global impressions scale (CGI) and confirmed by appropriate within-patient statistical analyses (Pazzaglia et al. 1998). Fourteen patients with an incomplete or inadequate response to nimodipine monotherapy were given a trial of blind carbamazepine augmentation. Four of these showed a clinically significant degree of improvement with the addition of carbamazepine as rated by the CGI change score and confirmed with *t*-tests.

Many of the responsive patients had failed multiple clinical trials of more traditional treatments, including lithium and a variety of other mood-stabilizing and antidepressant modalities. Among these were several patients with ultrarapid and ultra-ultrarapid (ultradian) cycling and several patients with recurrent brief depression. Several of the bipolar patients on either nimodipine monotherapy or combination therapy with carbamazepine were switched from the dihydropyridine nimodipine to the phenylalkylamine verapamil on a blind basis and failed to maintain their same degree of clinical improvement. On a blind basis, they re-responded to nimodipine and continued to maintain this degree of improvement with the transition to another dihydropyridine, isradipine. These data suggest that, at least in these few bipolar patients, there may not be a cross responsiveness among all of the L-type calcium channel blockers. The dihydropyridines, with their different site of action inside the calcium channel and different biochemical properties (Triggle 1992), may be preferable to the phenylalkylamines. However, a more formal comparable clinical trial in larger numbers of patients is required to confirm these differential preliminary observations in a few patients with confirmed responses.

LAMOTRIGINE

This newly approved anticonvulsant for adjunctive therapy in refractory epilepsies has received attention in the treatment of bipolar illness. Lamotrigine has interesting clinical properties including inhibition of excitatory amino acid release and blockade of sodium channels (Messenheimer 1995). However, evidence indicates that lamotrigine may possess other actions not shared by carbamazepine (Brodie et al. 1995), because of its additional efficacy in inadequate responders to carbamazepine in both epilepsy studies and affective illness studies, as described below.

Calabrese (1996) reported a 69% response rate when lamotrigine was added to previously ineffective treatments for patients with recurrent affective illness and, in a few cases, used in monotherapy. Particularly good responses to depression were noted and showed a relatively rapid onset, including 27 of 39 (69%) in the first week or two of treatment with the 25-mg dose. This low dose was initiated and fully titrated to average doses of approximately 150 mg/day to avoid the reported high incidence of rash.

Relatively similar degrees of response have been observed by Frye et al. (1998) in our group in the initial patients entering a 6-week randomized comparison of lamotrigine to placebo and gabapentin. Seventeen of 33 (52%) patients responded to lamotrigine as marked or moderate on the CGI-BP. Again, both antidepressant and mood-stabilizing properties were evident in these pa-

Table 3. Calcium Channel Blockers in Affective Illness

Open Studies		Blind Studies	
Responders		Responders	
Verapamil (Phenylalkylamine)		Verapamil (Phenylalkylamine)	
Gitlin & Weiss 1984	1/1 BP	Dubovsky et al. 1982	1/1 M
Brotman et al. 1986	6/6 M	Dubovsky & Franks 1983	2/2 M
Solomon & Williamson 1986	2/2 M	Giannini et al. 1984	10 M Equal to lithium, better than placebo
		Giannini et al. 1987	20 M Equal to lithium
Walton et al. 1996	?M	Giannini et al. 1989	10 M equal to lithium, better than valproate
Barton & Gitlin 1987	0/8 M (Acute) 1/4 M (Prophyl) 2/2 M ^a	Dubovsky et al. 1985	1/1 M ^a
Patterson 1987	1/1 M	Dose et al. 1986	7/8 M
Pollack & Rosenbaum 1987	1/1 UP	Dubovsky et al. 1986	5/7 M vs. 1/7 Li
Deicken 1990	1/1 BP	Dubovsky & Franks 1987	1/2 M Using Li-verap comb
Hoschl et al. 1992	4 BP-Dep/7 UP -verap more effective than antidep. and neurolep.	Hoschl & Kozeny 1989	12 M Sig. improved over neuroleptics, neuro + Li
		Garza-Trevino et al. 1990	17 M Equal to Li
		Garza-Trevino et al. 1992	12 M Equal to Li
		Hoschl 1983	1/1 Dep.
		Janicak et al. 1994	3/10 vs. 1/11 Li
Nimodipine (Dihydropyridine)		Nimodipine (Dihydropyridine)	
Brunet et al. 1990	6/6 M	Pazzaglia et al. 1993; 1998	7/23 BP 0/4 UP
Manna 1991 ^b	12 M -greatest improv. with Li + Nimod, vs. Li alone or Nimod alone	McDermut et al. 1995	3/3 RBD
		Eckmann, 1985a (2)	27/30 Dep 29/30 Dep
Goodnick 1995	2/2 BP	Montenegro et al. 1985	22/37 able to D/C with amitriptyline or nimodipine vs. 1/38 able to D/C on placebo
Grunze et al. 1996	1/1 BP (Li + Nimod)		
Walden et al. 1994	6/7 Dep.	Ban et al. 1990	87 patients on nimodipine, 88 patients on placebo - in elderly patients with cognitive decline, sig. more favorable changes in depressive symptomatology with nimodipine
Flunarizine (Dihydropyridine)		Flunarizine (Dihydropyridine)	
Lindelius & Nilsson 1992	1/1 M	Eckmann 1985b	14/17 Dep
Diltiazem (Benzothiazepine)		Isradipine (Dihydropyridine)	
Caillard 1985	5/5 M	McDermut et al. 1995; Pazzaglia et al. 1998	2/2 BP Nimodipine responders
Nifedipine (Dihydropyridine)			
Eccleston & Cole 1990	0/1 UP		
Moderate to Marked Responders	35/48 (73%)		125/178 (70%)

Abbreviations: BP = Bipolar Disorder; M = Mania; Dep. = Depression; UP = Unipolar; RBD = Recurrent Brief Depression.

^a Drug-induced hypomania.^b Lithium and nimodipine combination in prophylaxis better than either drug alone.

tients as compared with the placebo phase. Much work remains to delineate the clinical spectrum of efficacy of lamotrigine in refractory affectively ill patients, but the preliminary open observations of Calabrese (1996) and double-blind monotherapy studies of Frye et al. (1998) suggest that this agent could play an important role in the pharmacotherapy of bipolar illness.

GABAPENTIN

Gabapentin has important effects as an adjunctive treatment of refractory epilepsies and has a variety of purported mechanisms of action with indirect effects on γ -aminobutyric acid (GABA), such as affecting the GABA transporter and leading to increased levels of GABA in the central nervous system (Beydoun et al. 1995). Its potential for mood stabilization is just beginning to be explored, with preliminary reports of some success (McElroy et al. personal communication, Suppes et al. personal communication, Young et al., 1997) in open clinical observations, and responsivity in 9 of the first 33 patients (27%) to be studied in a randomized crossover as compared with placebo and lamotrigine, as noted above (Frye et al. 1998). Because gabapentin is not metabolized in the liver and is excreted in the kidney, and has few pharmacokinetic interactions with other agents, its positive side effects profile and lack of interaction with other drugs makes it a particularly appealing agent for adjunctive therapy, should it prove useful in further clinical trials.

HIGH-POTENCY BENZODIAZEPINES

The high-potency anticonvulsant benzodiazepines, such as clonazepam and lorazepam, are widely used in the treatment of acute mania and in the anxiety and insomnia of acute depression. The overall antimanic and mood-stabilizing effects of these agents has not yet been adequately delineated (Table 4). However, it is recommended that clinical use proceed with these agents in lieu of neuroleptics (with their liabilities for acute Parkinsonian side-effects and longer-term tardive dyskinesia) for patients with mania, agitation, insomnia, and anxiety breaking-through other treatments.

The increasing use of benzodiazepines is to be encouraged in light of the recent data of Sernyak et al. (1994), who reported that once manic patients are placed on neuroleptics, they are often continued on neuroleptics for extended periods of time, putting patients at greater risk for tardive dyskinesia, which is reported to be a very high 20 to 40% incidence rate in most studies of patients with bipolar illness (Hunt and Silverstone 1991). Further clinical trials are needed to

delineate the acute antimanic efficacy of benzodiazepines in monotherapy, although their adjunctive use, particularly in place of neuroleptics, would seem to have considerable merit, based even on the modicum of preliminary data available.

ATYPICAL NEUROLEPTICS

The atypical neuroleptics, such as clozapine, are now being used more widely with some success in the treatment of dysphoric mania and rapid cycling (Suppes et al. 1992; Calabrese and Woyshtville 1995; Calabrese et al. 1996; Frye et al. 1996). Although seizures are a side effect of clozapine, one study reports that clozapine might have some effects in inhibiting kindled seizure evolution (Graham and Kokkinidis 1993). Denney and Stevens (1995) have also postulated that the microconvulsive properties of clozapine could be related to its profile of clinical efficacy and have noted that patients cotreated with valproate seem to have less robust responses than those who are not so treated. These observations remain to be more systematically documented, but they raise a variety of intriguing possibilities in relation to convulsant and anticonvulsant mechanisms of psychotropic drug action.

Olanzapine and a whole group of atypical neuroleptics (Tamminga and Lahti 1996) are close to FDA approval in addition to risperidone and seroquel, and it is hoped that many of these agents will have positive clozapine-like properties without the liability of blood dyscrasias in the treatment of otherwise refractory bipolar illness.

REPEATED TRANSCRANIAL MAGNETIC STIMULATION (rTMS) OF THE BRAIN

This modality is just beginning to be explored in the treatment of conventional and refractory depression (Table 5). George et al. (1995) in our group first reported that stimulation with rTMS utilizing 20 Hz for 20 min over the left frontal cortex led to improvement in two of the first six patients. This finding led to a randomized design compared with sham, which also showed statistically significant improvement with rTMS (George et al. 1997). These studies were followed by another (Pascual-Leone et al. 1996) reporting 11 of 17 psychotic depressed patients responded to left frontal rTMS but not right frontal cortex or vertex rTMS. Five stimulations in that series led to clinical improvement lasting approximately 2 weeks.

These very exciting preliminary data require further elucidation in order to define the parameters and localities of stimulation that optimally produce antidepressant effects. Because low-frequency stimulation (1 Hz for 15 min) of the amygdala ("quenching") has dra-

Table 4. Partially Controlled Studies of Clonazepam and Lorazepam in Acute Mania

Study	N	Design	Addl Medication	Duration	Clon/Lor Doses	Outcome
Chouinard et al. (1983)	11	Double-blind crossover Clon vs. Li	Hal	10 days	2–16 mg daily Flexible	Clon = Li
Busch et al. (1989)	60	Retrospective, historical controls Lor-Cpz vs. Cpz	Li ECT CBZ	39 ± 20 days	310 mg Cpz ^b vs. 1.6 mg Lor/day	Lor-Cpz > Cpz
Bradwejn et al. (1990)	24	Double-blind Clon vs. Lor	None	14 days	6–22 mg daily Flexible	Lor > Clon
Edwards et al. (1991)	40	Double-blind Clon vs. P	Cpz	5 days	6 mg daily Fixed	Clon > P
Lenox et al. (1992)	20	Double-blind lithium plus Lor or-Hal	None	Variable ^a	8.8 ± 4.2 mg (mean ± SE) Flexible	Lor ≈ Hal
Chouinard et al. (1993)	35	Double-blind Clon vs. Hal Li after 1 week	None	14 days, min	8 mg daily, initially Flexible	Hal > Clon

^a Patients under observation until response or censoring, according to the survival analytical approach.

^b Cpz and Lor equivalents used.

Benzodiazepine doses converted to Lor equivalents according to method developed by Hyman and Arana (1987).

Nonbenzodiazepines sedative hypnotics converted to lorazepam equivalents by following method: chloral hydrate 500 mg = pentobarbital 100 mg = lorazepam 1 mg (clinical estimate) (Busch et al. 1989).

Clon, Clonazepam; Lor, Lorazepam; Li, Lithium; Hal, Haloperidol; Cpz, Chlorpromazine; P, Placebo; ECT, Electroconvulsive Therapy; CBZ, Carbamazepine.

matic anticonvulsant effects on kindled seizures (Weiss et al. 1995b), it is possible that low-frequency stimulation may increase inhibition and decrease hyperactivity circuits. However, more recent data indicate that a small direct current of 10–15 μ A is the critical variable in quenching (Weiss et al., 1998, unpublished data).

Should preliminary observations with the rTMS be supported in subsequent clinical trials, they would have very interesting implications for the mechanism of action of electroconvulsive therapy (ECT), which had always been presumably linked to the generation of a seizure. In rTMS, a seizure is not generated, and there are no subjective reports of cognitive clouding or impairment similar to that often induced with ECT. It is

possible that rTMS is more directly engaging the mechanism generated after a ECT seizure and that these rTMS effects are related to its potential clinical antidepressant profile. The molecular mechanisms require further elucidation, but the clinical and research potential for rTMS in discretely stimulating areas of the brain remains an exciting frontier.

CONCLUSION

Two decades ago lithium, as supplemented by neuroleptics and antidepressants, was virtually the only putative mood-stabilizing agent available for bipolar ill-

Table 5. Repeated Transcranial Magnetic Stimulation (rTMS) in Affective Illness

Patients	Design	Duration	Frequency	% Motor Threshold	Location	Response
Refractory depressed (George et al. 1995)	Open	5 Days	20 Hz	80%	Left frontal	2 of 6 Responded
Psychotic depressed (Pascual-Leone et al. 1996)	Sham vs. region	5 Days	10 Hz	90%	Left frontal, right frontal, and occipital	11 of 17 Responded to left frontal stimulation
Psychotic depressed (Catalá et al. 1996)	Left vs. right	2 Weeks	10 Hz	110%	Left and right prefrontal	7 of 7 Improved with left, but not right stimulation
Depressed outpatients (George et al. 1997)	Sham vs. active crossover	2 Weeks	20 Hz	80%	Left frontal	Significant improvement over sham (N = 12)
Depressed inpatients (Kimbrell et al. 1998, unpublished data)	Sham vs. frequency	10 Days	1 Hz vs. 20 Hz	80%	Left frontal	Opposite effects in different patients
Depressed inpatients (George et al. 1998, unpublished data)	Sham vs. frequency	2 Weeks	5 Hz vs. 20 Hz	80%	Left frontal	In progress

ness. Increasingly, it has been recognized that lithium alone or in combination with adjunctive strategies is inadequate for a very substantial group of bipolar patients. Now a variety of putative mood-stabilizing agents are available for acute and long-term therapeutics and for devising the optimal treatment algorithms in the most appropriate combination. The sequencing of these agents remains a very important issue for further clinical work and systematic clinical trials in methodological exploration. Over each of the last five 5-year epochs at the National Institute for Mental Health (NIMH), we have found that approximately 80% of our patients were able to be discharged with marked or moderate improvement. Twenty years ago, three-quarters of the patients were discharged from our clinical research unit on monotherapy; in the last 5-year epoch, only 25% of the patients were discharged on monotherapy, and the average was 3 drugs per patient. Thus, rational combination therapy seems to be a requirement for clinical stabilization in many instances (Frye 1996). Defining the principles for optimum combination of these agents (Post et al. 1996b; Post et al. 1997) remains a very important task for future research.

REFERENCES

- Aagaard J, Vestergaard P (1990): Predictors of outcome in prophylactic lithium treatment: A 2-year prospective study. *J Affect Dis* 18:259–266
- Ballenger JC, Post RM (1978): Therapeutic effects of carbamazepine in affective illness: Preliminary report. *Commun Psychopharmacol* 2:159–175
- Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, Cagliaris N, Sterlichio M, Capurso A, Tomasi NA (1990): Nimodipine in the treatment of old age dementias. *Prog Neuropsychopharmacol Biol Psych* 14:525–551
- Barton BM, Gitlin MJ (1987): Verapamil in treatment-resistant mania: An open trial. *J Clin Psychopharmacol* 7:101–103
- Bellaire W, Demisch K, Stoll K-D (1990): Carbamazepine vs. Lithium. Application in the Prophylaxis of Recurrent Affective and Schizoaffective Psychoses. *Munch Med Wschr* 132:S82–S86
- Beydoun A, Uthman BM, Sackellares JC (1995): Gabapentin: Pharmacokinetics, efficacy, and safety. *Clin Neuropharm* 18:469–481
- Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD (1994): Efficacy of divalproex vs. lithium and placebo in the treatment of mania. *JAMA* 271:918–924
- Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, Calabrese JR, Goodnick P, Small JG, Rush AJ, Kimmel SE, Risch SC, Morris DD (1996): Relation of serum valproate concentration to response in mania. *Am J Psychiat* 153:765–770
- Bradwejn J, Shriqui C, Koszycki D, Meterissian G (1990): Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. *J Clin Psychopharmacol* 10:403–408
- Brodie MJ, Richens A, Yuen AW (1995): Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. *Lancet* 345:476–479
- Brotman AW, Farhadi AM, Gelenberg AJ (1986): Verapamil treatment of acute mania. *J Clin Psychiat* 47:136–138
- Brown D, Silverstone T, Cookson J (1989): Carbamazepine compared to haloperidol in acute mania. *Int Clin Psychopharmacol* 4:229–238
- Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, Darcourt G (1990): Open trial of a calcium antagonist, nimodipine in acute mania. *Clin Neuropharmacol* 13:224–228
- Busch FN, Miller FT, Weiden PJ (1989): A comparison of two adjunctive treatment strategies in acute mania. *J Clin Psychiat* 50:453–455
- Cabrera JF, Muhlbauser HD, Schley J, Stoll KD, Muller-Oerlinghausen B (1986): Long-term randomized clinical trial on oxcarbazepine vs. lithium in bipolar and schizoaffective disorders: Preliminary results. *Pharmacopsychiatry* 19:282–283
- Caillard V (1985): Treatment of mania using a calcium antagonist—Preliminary trial. *Neuropsychobiology* 14:23–26
- Calabrese JR, Delucchi GA (1989): Phenomenology of rapid cycling manic depression and its treatment with valproate. *J Clin Psychiat* 50:30–34
- Calabrese JR, Delucchi GA (1990): Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. *Am J Psychiat* 147:431–434
- Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC (1992): Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. *J Clin Psychopharmacol* 12:53S–56S
- Calabrese JR, Woyshville MJ (1995): A medication algorithm for treatment of bipolar rapid cycling? *J Clin Psychiatry* 56 (Suppl 3):11–18
- Calabrese C (1996): Lamotrigine in treatment refractory manic depression. *J Eur College Neuropsychopharmacology* 6:98
- Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY (1996): Clozapine for treatment-refractory mania. *Am J Psychiat* 153:759–764
- Catalá MD, Rubio B, Pascual-Leone A (1996): Lateralized effect of rapid-rate transcranial magnetic stimulation of dorsolateral prefrontal cortex on depression. *Neurology* 46:A327 (abstract #S28.005)
- Chouinard G, Young SN, Annable L (1983): Antimanic effect of clonazepam. *Biol Psychiat* 18:451–466
- Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N (1993): A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. *Can J Psychiat* 38:S114–S121
- Coxhead N, Silverstone T, Cookson J (1992): Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. *Acta Psychiat Scand* 85:114–118
- Deicken RF (1990): Verapamil treatment of bipolar depression. *J Clin Psychopharmacol* 10:148–149

- Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM (1997): Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. *J Clin Psychiatry* 58:470–478
- Denney D, Stevens JR (1995): Clozapine and seizures. *Biol Psychiat* 37:427–433
- Desai NG, Gangadhar BN, Channabasavanna SM, Shetty KT (1987): Carbamazepine hastens therapeutic action of lithium in mania. *Proceedings of the International Conference on New Directions in Affective Disorders*, 97
- Di Costanzo E, Schifano F (1991): Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. *Acta Psychiat Scand* 83:456–459
- Dose M, Emrich HM, Cording-Tommel C, Von Zerssen D (1986): Use of calcium antagonists in mania. *Psychoneuroendocrinology* 11:241–243
- Dubovsky SL, Franks RD, Lifschitz M, Coen P (1982): Effectiveness of verapamil in the treatment of a manic patient. *Am J Psychiat* 139:502–504
- Dubovsky SL, Franks RD (1983): Intracellular calcium in affective disorders: A review and an hypothesis. *Biol Psychiat* 18:781–797
- Dubovsky S, Franks R, Schrier D (1985): Phenelzine-induced hypomania: Effect of verapamil. *Biol Psychiat* 20:1009–1014
- Dubovsky SL, Franks RD, Allen S (1986): Calcium antagonists in mania: A double-blind study of verapamil. *Psychiat Res* 18:309–320
- Dubovsky SL, Franks RD (1987): Verapamil: A new anti-manic drug with potential interactions with lithium. *J Clin Psychiat* 48:371–372
- Eccleston D, Cole AJ (1990): Calcium-channel blockade and depressive illness. *Br J Psychiat* 156:889–891
- Eckmann F (1985a): Clinical studies on nimodipine in the treatment of patients with depressive syndromes in the second half of life. In Betz E, Deck K, Hoffmeister F (eds), *Nimodipine: Pharmacological and Clinical Studies*. Stuttgart, Schattauer, pp 307–313
- Eckmann VF (1985b): Double-blind clinical study with the calcium antagonist flunarizine in cerebral circulatory disturbances. *Arzneimittelforschung* 35:1276–1279
- Edwards R, Stephenson U, Flewett T (1991): Clonazepam in acute mania: A double-blind trial. *Aust N Z J Psychiat* 25:238–242
- Elphick M, Lyons F, Cowen PJ (1988): Low tolerability of carbamazepine in psychiatric patients may restrict its clinical usefulness. *J Psychopharmacol* 2:1–4
- Emrich HM, Dose M, Von Zerssen D (1984): Action of sodium-valproate and of oxcarbazepine in patients with affective disorders. In Emrich HM, Okuma T, Muller AA (eds), *Anticonvulsants in Affective Disorders*. Amsterdam, Excerpta Medica, pp 45–55
- Emrich HM, Dose M, Von Zerssen D (1985): The use of sodium valproate, carbamazepine, and oxcarbazepine in patients with affective disorders. *J Aff Dis* 8:243–250
- Emrich HM (1990): Studies with oxcarbazepine (Trileptal) in acute mania. *Int Clin Psychopharmacol* 5:83–88
- Fawcett J (1988): Personal Communication, March
- Frankenburg FR, Tohen M, Cohen BM, Lipinski JF, Jr. (1988): Long-term response to carbamazepine: A retrospective study. *J Clin Psychopharmacol* 8:130–132
- Freedman DD, Waters DD (1987): 'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications. *Drugs* 34:578–598
- Fromm GH, Terrence CF (1987): Effects of antiepileptic drugs on the brain-stem. In Fromm GH, Faingold CL, Browning RA, Burnham WM (eds), *Epilepsy and the Reticular Formation*. New York, Alan R. Liss, pp 119–136
- Frye MA (1996): The increasing use of polypharmacy for refractory mood disorders: Twenty-five years of study (abstract). *APA New Research Program and Abstracts*, pp 151–152 (abstract NR312)
- Frye MA, Altshuler LL, Bitran J (1996): Clozapine in rapid cycling bipolar disorder. *J Clin Psychopharmacol* 16:87–90
- Frye MA, Ketter TA, Kimbrell TA, Dunn RM, Speer AM, Osuch EA, Luckenbaugh D, Cora-Locatelli G, Leverich GS, Post RM (1998): Gabapentin and lamotrigine monotherapy in mood disorder (abstract). *Syllabus and Proceedings Summary of the 151st Meeting of the American Psychiatric Association* (in press).
- Garza-Trevino ES (1990): Verapamil versus lithium in acute mania. *Abstracts of the 143rd Annual Meeting of the American Psychiatric Association*: 78 (abstract #27)
- Garza-Trevino ES, Overall JE, Hollister LE (1992): Verapamil versus lithium in acute mania. *Am J Psychiat* 149:121–122
- Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J (1989): Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. *N Engl J Med* 321:1489–1493
- George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM (1995): Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. *NeuroReport* 6:1853–1856
- George MS, Wassermann EM, Williams WA, Kimbrell TA, Little JT, Hallett M, Post RM (1996): Daily left prefrontal repetitive transcranial magnetic stimulation in outpatient depression: Initial results of a double-blind placebo controlled crossover trial (abstract). *APA New Research Program and Abstracts*: 280 (abstract NR768)
- George MS, Wassermann EM, Kimbrell TA, Little JT, Williams WE, Danielson AL, Greenberg BD, Hallett M, Post RM (1997): Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: A placebo-controlled crossover trial. *Am J Psychiatry* 154:1752–1756
- Giannini AJ, House WL, Loiselle RH (1984): Antimanic effects of verapamil. *Am J Psychiat* 141:1602–1603
- Giannini AJ, Taraszewski R, Loiselle RH (1987): Verapamil and lithium in maintenance therapy of manic patients. *J Clin Pharmacol* 27:980–982
- Giannini AJ, Sullivan BS, Folts DJ (1989): Comparison of lithium carbonate, valproic acid and verapamil in the treatment of manic symptoms. *J Clin Pharmacol* 29:832 (abstract #1)
- Gitlin MJ, Weiss J (1984): Verapamil as maintenance treatment in bipolar illness: a case report. *J Clin Psychopharmacol* 4:341–343
- Gitlin MJ, Swendsen J, Heller TL, Hammen C (1995): Relapse

- and impairment in bipolar disorder. *Am J Psychiat* 152:1635–1640
- Goncalves N, Stoll KD (1985): Carbamazepine in manic syndromes. A controlled double-blind study. *Nervenarzt* 56:43–47
- Goodnick PJ (1995): Nimodipine treatment of rapid cycling bipolar disorder. *J Clin Psychiat* 56:330
- Graham SR, Kokkinidis L (1993): Clozapine inhibits limbic system kindling: Implications for antipsychotic action. *Brain Res Bull* 30:597–605
- Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1997a): Lithium versus carbamazepine in the maintenance treatment of bipolar disorders—a randomised study. *J Affect Disord* 43:151–161
- Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1997b): Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. *Eur Arch Psychiatry Clin Neurosci* 247:42–50
- Grossi E, Sacchetti E, Vita A, Conte G, Faravelli C, Hautmann G, Zerbi D, Mesina AM, Drago F, Motta A (1984): Carbamazepine vs. chlorpromazine in mania: A double-blind trial. In Emrich HM, Okuma T, Muller AA (eds), *Anticonvulsants in Affective Disorders*. Amsterdam, Excerpta Medica, pp 177–187
- Grunze H, Walden J, Wolf R, Berger M (1996): Combined treatment with lithium and nimodipine in a bipolar I manic syndrome. *Prog Neuropsychopharmacol Biol Psychiat* 20:419–426
- Hoschl C (1983): Verapamil for depression? *Am J Psychiat* 140:1100
- Hoschl C, Kozeny J (1989): Verapamil in affective disorders: A controlled, double-blind study. *Biol Psychiat* 25:128–140
- Hoschl C, Vackova J, Janda B (1992): Mood stabilizing effect of verapamil. *Bratisl Lek Listy* 93:208–209
- Hunt N, Silverstone T (1991): Tardive dyskinesia in bipolar affective disorder: A catchment area study. *Int Clin Psychopharmacol* 6:45–50
- Hyman SE, Arana GW (1987): *Handbook of Psychiatric Drug Therapy*. Boston, Little Brown
- Janicak PG, Pandey G, Sharma R, Peterson J, Leach A, Davis JM (1994): Verapamil for acute mania: Preliminary results from a double-blind, placebo-controlled study (abstract). *Proceedings of 1st International Conference on Bipolar Disorder*, 46
- Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA (1993): Valproate oral loading in the treatment of acute mania. *J Clin Psychiat* 54:305–308
- Ketter TA, Kimbrell TA, George MS, Stein RM, Willis MW, Benson BE, Frye MA, Cora-Locatelli G, Post RM (1996): Baseline hypermetabolism may predict carbamazepine response and hypometabolism nimodipine response in mood disorders. *Abstracts of the XXth Collegium Internationale Neuro-Psychopharmacologicum Congress*:10 (abstract #O-5-6)
- Kishimoto A, Okuma T (1986): Antimanic and prophylactic effects of carbamazepine in affective disorders. In Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM (eds), *Biological Psychiatry* 1985. Amsterdam, Elsevier, pp 883–885
- Klein E, Bental E, Lerer B, Belmaker RH (1984): Carbamazepine and haloperidol vs. placebo and haloperidol in excited psychoses. *Arch Gen Psychiat* 41:165–170
- Koukopoulos A, Reginaldi D, Minnai G, Serra G, Pani L, Johnson FN (1995): The long-term prophylaxis of affective disorders. *Adv Biochem Psychopharmacol* 49:127–147
- Lambert PA (1984): Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In Emrich HM, Okuma T, Muller AA (eds), *Anticonvulsants in Affective Disorders*. Amsterdam, Excerpta Medica, pp 33–44
- Lambert PA, Venaud G (1995): Comparative study of valpromide vs. lithium as prophylactic treatments in affective disorders. *Nervure J Psychiatrie* 1–9
- Lenox RH, Newhouse PA, Creelman WL, Whitaker TM (1992): Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study. *J Clin Psychiat* 53:47–52
- Lenzi A, Lazzarini F, Grossi E, Massimetti G, Placidi GF (1986): Use of carbamazepine in acute psychosis: A controlled study. *J Int Med Res* 14:78–84
- Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S (1987): Carbamazepine versus lithium in mania: A double-blind study. *J Clin Psychiat* 48:89–93
- Lindelius R, Nilsson CG (1992): Flunarizine as maintenance treatment of a patient with bipolar disorder. *Am J Psychiat* 149:139
- Lusznat RM, Murphy DP, Nunn CM (1988): Carbamazepine vs. lithium in the treatment and prophylaxis of mania. *Br J Psychiat* 153:198–204
- Maj M, Pirozzi R, Kemali D (1989): Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. *Psychopharmacology (Berlin)* 98: 535–538
- Manna V (1991): Bipolar affective disorders and role of intraneuronal calcium. Therapeutic effects of the treatment with lithium salts and/or calcium antagonist in patients with rapid polar inversion. *Minerva Med* 82:757–763
- McDermut W, Pazzaglia PJ, Huggins T, Mikalaukas K, Leverich GS, Ketter TA, Bartko J, Post RM (1995): Use of single case analyses in off-on-off-on trials in affective illness: A demonstration of the efficacy of nimodipine. *Depression* 2:259–271
- Messenheimer JA (1995): Lamotrigine. *Epilepsia* 36:S87–S94
- Moller HJ, Kissling W, Riehl T, Bauml J, Binz U, Wendt G (1989): Double-blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. *Prog Neuropsychopharmacol Biol Psychiat* 13:127–136
- Montenegro R, Comide E, Castro JM (1985): Nimodipine in the treatment of involuntal depressive syndrome. In Betz E, Deck K, Hoffmeister F (eds), *Nimodipine: Pharmacological and Clinical Studies*. Stuttgart, Schattauer, pp 307–313
- Mosolov SN (1991): Comparative effectiveness of preventive use of lithium carbonate, carbamazepine and sodium valproate in affective and schizoaffective psychoses. *Zh Nevropatol Psikhiatr* 91:78–83
- Muller AA, Stoll K-D (1984): Carbamazepine and oxcarbam-

- azepine in the treatment of manic syndromes: studies in Germany. In Emrich HM, Okuma T, Muller AA (eds), *Anticonvulsants in Affective Disorders*. Amsterdam, Excerpta Medica, pp 139–147
- O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE (1991): Outcome of bipolar disorder on long-term treatment with lithium. *Br J Psychiat* 159:123–129
- Okuma T, Inanaga K, Otsuki S, Sarai K (1979): Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study. *Psychopharmacology* 66:211–217
- Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe M (1981): A preliminary double-blind study of the efficacy of carbamazepine in prophylaxis of manic-depressive illness. *Psychopharmacology* 73:95–96
- Okuma T, Yamashita I, Takahashi R, Itoh H, Kurihara M, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K (1988): Double-blind controlled studies on the therapeutic efficacy of carbamazepine in affective and schizophrenic patients. *Psychopharmacology* 96:102 (abstract #TH18.05)
- Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K (1990): Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. *Pharmacopsychiatry* 23:143–150
- Okuma T (1993): Effects of carbamazepine and lithium on affective disorders. *Neuropsychobiology* 27:138–145
- Pani L, Kuzmin A, Diana M, De Montis G, Gessa GL, Rossetti ZL (1990): Calcium receptor antagonists modify cocaine effects in the central nervous system differently. *Eur J Pharmacol* 190:217–221
- Pascual-Leone A, Rubio B, Pallardo F, Catala MD (1996): Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. *Lancet* 348:233–237
- Patterson JF (1987): Treatment of acute mania with verapamil. *J Clin Psychopharmacol* 7:206–207
- Pazzaglia PJ, Post RM (1992): Contingent tolerance and reresponse to carbamazepine: A case study in a patient with trigeminal neuralgia and bipolar disorder. *J Neuropsychiat Clin Neurosci* 4:76–81
- Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB (1993): Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. *Psychiat Res* 49:257–272
- Pazzaglia PJ, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA, George MS, Kimbrell TA, Leverich GS, Cora-Locatelli G, Luckenbaugh D (1998): Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. *J Clin Psychopharmacol* (in press)
- Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS (1986): The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. *J Clin Psychiat* 47:490–494
- Pollack MH, Rosenbaum JF (1987): Verapamil in the treatment of recurrent unipolar depression. *Biol Psychiat* 22:779–782
- Pope HG, McElroy SL, Keck PE, Jr., Hudson JI (1991): Valproate in the treatment of acute mania. *Arch Gen Psychiat* 48:62–68
- Post RM, Uhde TW, Ballenger JC, Squillace KM (1983): Prophylactic efficacy of carbamazepine in manic-depressive illness. *Am J Psychiat* 140:1602–1604
- Post RM, Ballenger JC, Uhde TW, Bunney WEJ (1984a): Efficacy of carbamazepine in manic-depressive illness: Implications for underlying mechanisms. In Post RM, Ballenger JC (eds), *Neurobiology of Mood Disorders*. Baltimore, Williams & Wilkins, pp 777–816
- Post RM, Berrettini WH, Uhde TW, Kellner CH (1984b): Selective response to the anticonvulsant carbamazepine in manic-depressive illness: A case study. *J Clin Psychopharmacol* 4:178–185
- Post RM, Uhde TW, Roy-Byrne PP, Joffe RT (1986): Antidepressant effects of carbamazepine. *Am J Psychiat* 143: 29–34
- Post RM, Uhde TW, Roy-Byrne PP, Joffe RT (1987): Correlates of antimanic response to carbamazepine. *Psychiat Res* 21:71–83
- Post RM (1989): Use of anticonvulsants in the treatment of manic-depressive illness. In Post RM, Trimble MR, Pippenger CE (eds), *Clinical Use of Anticonvulsants in Psychiatric Disorders*. New York, Demos Publications, pp 113–152
- Post RM, Leverich GS, Rosoff AS, Altshuler LL (1990): Carbamazepine prophylaxis in refractory affective disorders: A focus on long-term follow-up. *J Clin Psychopharmacol* 10:318–327
- Post RM, Leverich GS, Altshuler L, Mikalaukas K (1992): Lithium discontinuation-induced refractoriness: Preliminary observations. *Am J Psychiat* 149:1727–1729
- Post RM, Leverich GS, Pazzaglia PJ, Mikalaukas K, Denicoff K (1993): Lithium tolerance and discontinuation as pathways to refractoriness. In Birch NJ, Padgham C, Hughes MS (eds), *Lithium in Medicine and Biology*. Lancashire, UK, Marius Press, pp 71–84
- Post RM, Ketter TA, Pazzaglia PJ, Denicoff K, Marangell L, George MS (1994): Anticonvulsants in refractory mood disorders. In Nolen WA, Zohar J, Roose SP (eds), *Refractory Depression: Current Strategies and Future Directions*. Chichester, England, John Wiley & Sons, pp 97–114
- Post RM, Ketter TA, Denicoff K, Pazzaglia PJ, Leverich GS, Marangell LB, Callahan AM, George MS, Frye MA (1996a): The place of anticonvulsant therapy in bipolar illness. *Psychopharmacology (Berlin)* 128:115–129
- Post RM, Ketter TA, Pazzaglia PJ, Denicoff K, George MS, Callahan A, Leverich G, Frye M (1996b): Rational polypharmacy in the bipolar affective disorders. *Epilepsy Res* 11 (suppl):153–180
- Post RM, Denicoff KD, Frye MA, Leverich GS (1997): Algorithms for bipolar mania. In Rush AJ (ed), *Mood Disorders. Systematic Medication Management*. Basel, Karger, pp 114–145
- Prien RF, Gelenberg AJ (1989): Alternatives to lithium for preventive treatment of bipolar disorder. *Am J Psychiat* 146:840–848
- Roy-Byrne PP, Joffe RT, Uhde TW, Post RM (1984): Carbamazepine and thyroid function in affectively ill patients: Clinical and theoretical implications. *Arch Gen Psychiat* 41:1150–1153

- Sarantidis D, Waters B (1981): Predictors of lithium prophylaxis effectiveness. *Prog Neuropsychopharmacol* 5:507–510
- Schaff MR, Fawcett J, Zajecka JM (1993): Divalproex sodium in the treatment of refractory affective disorders. *J Clin Psychiat* 54:380–384
- Sernyak MJ, Griffin RA, Johnson RM, Pearsall HR, Wexler BE, Woods SW (1994): Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. *Am J Psychiat* 151:133–135
- Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, Small IF (1991): Carbamazepine compared with lithium in the treatment of mania. *Arch Gen Psychiat* 48:915–921
- Solomon I, Williamson P (1986): Verapamil in bipolar illness. *Can J Psychiat* 31:442–444
- Stoll KD, Bisson HE, Fischer E, Gammel G, Goncalves N, Krober HL, Muldner H, Nadler A, Troyke P (1986): Carbamazepine versus haloperidol in manic syndromes—First report of a multicentric study in Germany. In Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM (eds), *Biological Psychiatry* 1985. Amsterdam, Elsevier, pp 332–334
- Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO (1992): Clozapine in the treatment of dysphoric mania. *Biol Psychiat* 32:270–280
- Svestka J, Nahunek K, Ceskova E, Korbicka J (1985): Carbamazepine prophylaxis of affective psychoses (intraindividual comparison with lithium carbonate). *Activ Nerv Sup* 27:261–262
- Tamminga CA, Lahti AC (1996): The new generation of antipsychotic drugs. *Int Clin Psychopharmacol* 11:73–76
- Triggle DJ (1992): Biochemical and pharmacologic differences among calcium channel antagonists: Clinical implications. In Epstein M (ed), *Calcium Antagonists in Clinical Medicine*. Philadelphia, Hanley & Belfus, pp 1–27
- Vestergaard P (1992): Treatment and prevention of mania: A Scandinavian perspective. *Neuropsychopharmacology* 7:249–260
- Walden J, Grunze H, Hellhammer D, Fritze J, Berger M (1994): Treatment of depressive episodes with the calcium antagonist nimodipine: Single case reports. *Neuropsychopharmacology* 10:233S.
- Walton SA, Berk M, Brook S (1996): Superiority of lithium over verapamil in mania: A randomized controlled trial. *J Eur College Neuropsychopharmacol* 6:9–10
- Watkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM (1987): The effect of carbamazepine and lithium on remission from affective illness. *Br J Psychiat* 150:180–182
- Weiss SRB, Clark M, Rosen JB, Smith MA, Post RM (1995a): Contingent tolerance to the anticonvulsant effects of carbamazepine: Relationship to loss of endogenous adaptive mechanisms. *Brain Res Rev* 20:305–325
- Weiss SRB, Li XL, Rosen JB, LiH, Heynen T, Post RM (1995b): Quenching: Inhibition of development and expression of amygdala kindled seizures with low frequency stimulation. *NeuroReport* 6:2171–2176
- Wolf C, Berky M, Kovacs G (1997): Carbamazepine versus lithium in the prophylaxis of bipolar affective disorders: A randomised, double-blind 1-year study in 168 patients (abstract). *Eur Neuropsychopharmacol* 7(suppl. 2):S176
- Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT (1997): Acute treatment of bipolar depression with garapentin. *Biol Psychiat* 42:851–853